Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Meeting on the Med 2022 | Developing a therapeutic cancer vaccine for patients with NSCLC

Eric Halioua, PDC*line Pharma, Liege, Belgium, comments the development of PDC*lung, a novel therapeutic plasmacytoid dendritic cell (PDC)-derived vaccine for patients with non-small cell lung cancer (NSCLC). He describes the mechanism of action of the vaccine, where irradiated PDCs are loaded with peptides encoding various lung tumor antigens. A Phase I/II trial (NCT03970746) will assess the vaccine in 64 patients in either a high or low dose. This interview was conducted during Meeting on the Mediterranean 2022.